New treatment options for pulmonary arterial hypertension — the first selective IP-receptor agonist selexipag
Pulmonary arterial hypertension (PAH) is a rare chronic life-threatening disease. The treatment standards for PAH patients emphasize the need for early intervention and achievement of all treatment goals with the use of monotherapy or combinations. To date, strong evidence has been obtained that com...
Wedi'i Gadw mewn:
| Prif Awduron: | , , |
|---|---|
| Fformat: | Artigo |
| Iaith: | Russo |
| Cyhoeddwyd: |
«SILICEA-POLIGRAF» LLC
2019-12-01
|
| Cyfres: | Кардиоваскулярная терапия и профилактика |
| Pynciau: | |
| Mynediad Ar-lein: | https://cardiovascular.elpub.ru/jour/article/view/2384 |
| Tagiau: |
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|